Jacqueline A. Nicholas, MD, MPH - Setting the Stage for Bruton’s Tyrosine Kinase Inhibitors in Relapsing Multiple Sclerosis: Where Does the Evidence Stand?

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Busting Brain Myths: TikTok's Viral Neuroscientist 11 min · 24 Sep 2026 · Today with David McCullagh

We Investigated the Christian "Scam" Fronted by Tim Tebow 1h 17m · 24 Sep 2026 · Pablo Torre Finds Out

Trump threatens Iran in fiery UN speech. What's next? 14 min · 24 Sep 2026 · The Excerpt

Why Grit Isn’t Always Enough with Angela Duckworth 1h 3m · 24 Sep 2026 · The Curiosity Shop with Brené Brown and Adam Grant

Trump Wakes Up to Nightmare With Xi 17 min · 24 Sep 2026 · The MeidasTouch Podcast

Stress: The Science of Chilling Out 37 min · 24 Sep 2026 · Science Vs

Report any issue

Source

Recorded04 May 2023

Publisherc.answersincme.com ↗

Handlerec:10296365

Show notes

Please visit answersincme.com/BAV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses Bruton’s tyrosine kinase (BTK) inhibitors in relapsing multiple sclerosis (MS). Upon completion of this activity, participants should be better able to: Recognize the biologic rationale for therapeutically targeting BTK in MS; Describe the clinical impact of late-stage emerging BTK inhibitors in relapsing MS; and Outline clinical considerations for the future use of BTK inhibitors in the management of relapsing MS.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in